Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6.6Revenue $M3.2Net Margin (%)-594.3Altman Z-Score-25.9
Enterprise Value $M3.2EPS $-7.9Operating Margin %-610.7Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-594.2Higher ROA y-yN
Price/Book23.810-y EBITDA Growth Rate %--Quick Ratio1.1Cash flow > EarningsY
Price/Sales1.55-y EBITDA Growth Rate %--Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-220.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-649.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M3.5ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NBY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy12,000$0.47304.26view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy2,590,000$0.6216.67view
SIECZKAREK MARK MDirector 2015-03-03Buy166,666$0.6216.67view
Najafi RaminChairman 2015-03-03Buy166,666$0.6216.67view
Najafi RaminChairman 2014-12-12Buy50,000$0.65192.31view
PAULSON THOMAS JCFO 2014-12-12Buy10,000$0.68179.41view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy10,000$0.66187.88view
Najafi RaminChairman 2014-12-11Buy20,000$0.6216.67view
PAULSON THOMAS JCFO 2014-12-09Buy10,000$0.67183.58view
Najafi RaminChairman 2014-12-05Buy25,000$0.65192.31view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

    News about NBY:

    Articles On GuruFocus.com
    NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

    More From Other Websites
    NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
    NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
    3 Biotech Stocks Under $10 to Trade for Big Breakouts Jan 08 2016
    NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
    NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
    NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Dec 21 2015
    NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Dec 14 2015
    NovaBay Declares Reverse Stock Split Dec 11 2015
    NovaBay Declares Reverse Stock Split Dec 11 2015
    NOVABAY PHARMACEUTICALS, INC. Financials Dec 08 2015
    NovaBay Pharmaceuticals, Inc. Earnings Q3, 2015 Dec 02 2015
    NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 19 2015
    NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports... Nov 19 2015
    NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports... Nov 19 2015
    NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 16 2015
    NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to November 19 Nov 16 2015
    NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to November 19 Nov 16 2015
    New Study Shows Success Fighting Eye Mites Nov 11 2015
    NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to November 16 Nov 11 2015
    NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to November 16 Nov 11 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK